Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.

Shanghai Fosun Pharmaceutical (02196) announced that its subsidiary, Gismo Pharmaceuticals (Wuhan) Co., Ltd., a holding company of Shanghai Fosun Pharmaceutical Group, has had its drug registration application for the injection of Epirubicin Hydrochloride accepted by the National Medical Products Administration. This drug is a chemically developed drug by the group, intended for the treatment of acute leukemia. It can also be used in combination with other anticancer drugs for the treatment of Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. As of July 2025, the group has invested approximately 3.03 million RMB (unaudited) in research and development for this drug. According to the latest data from IQVIA CHPA, in 2024, the sales of Epirubicin Hydrochloride injection in mainland China (excluding Hong Kong, Macau, and Taiwan) were approximately 202 million RMB.